A phase II study of a short bevacizumab infusion in patients with metastatic colorectal cancer.
Ontology highlight
ABSTRACT:
DISEASE(S): Unresectable Metastatic/recurrent Colorectal Cancer
PROVIDER: 2640977 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
Similar Datasets
Project description:To identify insulin responsive genes in humans, in the first protocol, skeletal muscle biopsies from six non-diabetic subjects were obtained before and after a two-hour of hyperinsulinaemic (infusion rate 40 mU/m2/min) euglycemic clamp. A variable infusion of glucose (180 g/l) enriched with tritiated glucose (100 μCi/500 ml) maintained euglycemia during insulin infusion, with monitoring of plasma glucose concentration every 5 to 10 min during the basal and clamp periods using an automated glucose oxidation method (Glucose Analyzer 2, Beckman Instruments, Fullerton, CA). In the second protocol, skeletal muscle biopsies from six non-diabetic subjects were obtained before and after a 3-hour hyperinsulinemic (infusion rate 40 mU/m2/min) euglycemic clamp in order to increase the effects of insulin on gene expression. A variable infusion of glucose (180 g/l) was used to maintain euglycemia during insulin infusion with monitoring of plasma glucose concentration every 5 to 10 min using an automated glucose oxidation method (Glucose Analyzer 2, Beckman Instruments, Fullerton, CA). Keywords: dose response
2007-03-01 | GSE7146 | GEO
Project description:To identify insulin responsive genes in humans, in the first protocol, skeletal muscle biopsies from six non-diabetic subjects were obtained before and after a two-hour of hyperinsulinaemic (infusion rate 40 mU/m2/min) euglycemic clamp. A variable infusion of glucose (180 g/l) enriched with tritiated glucose (100 μCi/500 ml) maintained euglycemia during insulin infusion, with monitoring of plasma glucose concentration every 5 to 10 min during the basal and clamp periods using an automated glucose oxidation method (Glucose Analyzer 2, Beckman Instruments, Fullerton, CA). In the second protocol, skeletal muscle biopsies from six non-diabetic subjects were obtained before and after a 3-hour hyperinsulinemic (infusion rate 40 mU/m2/min) euglycemic clamp in order to increase the effects of insulin on gene expression. A variable infusion of glucose (180 g/l) was used to maintain euglycemia during insulin infusion with monitoring of plasma glucose concentration every 5 to 10 min using an automated glucose oxidation method (Glucose Analyzer 2, Beckman Instruments, Fullerton, CA). Keywords: dose response The muscle biopsies were obtained from the vastus lateralis muscle under local anesthesia before and after hyperinsulinaemic (infusion rate 40 mU/m2/min) euglycemic clamp
2007-03-01 | E-GEOD-7146 | biostudies-arrayexpress
Project description:This study looked for early response signals produced in UV-B irradiated leaves and induced in shielded leaves and shielded ears that modulate physiological responses in maize. Transcriptome profiling tracked changes in exposed and shielded organs. Metabolic profiling was examined for signaling molecules. The top 2 leaves were exposed to 10, 30, or 60 minutes of ~3x normal UV-B and then tissue samples were taken from all 3 tissue types. Over 250 transcripts are differentially expressed at least 2 fold in irradiated leaves by 10 min of UV-B. At 30 min this decreased to ~150 then increased to over 500 transcripts at 60 min. Different pathways are affected at the various time exposures and specific responses are modulated by the time of exposure. Shielded leaves had a smaller number of transcripts affected at each time point but over 60% were in common with the irradiated leaves results at 10 min. and ~20% overlaps were found at 30 and 60 min. Metabolite samples were analyzed after 5, 10, 15, 30, and 90 min of UV-B. We identified 14 compounds with a statistically significant change from untreated plants in at least one time point.
2011-07-31 | GSE30278 | GEO
Project description:Interventions: Bevacizumab is administered in 0.5mg/kg/min.
Primary outcome(s): Having onset of hypersensitivity reaction or not
Study Design: Single arm Non-randomized
| 2633596 | ecrin-mdr-crc
Project description:Interventions: To administer ramucirumab in a short period of time
Primary outcome(s): Incidence of infusion related reaction (any grade) at the first short-term infusion
Study Design: Single arm Non-randomized
| 2644505 | ecrin-mdr-crc
Project description:Interventions: Additional intravenous chlorpheniramine 10 mg at 30 minutes before oxaliplatin infusion and oxaliplatin was given in a 3-hour intravenous infusion for all 6 planned cycles of FOLFOX/FOLFIRINOX regimens and 4 planned cycles of CAPOX regimen.,In control group, oxaliplatin was infused in two-hour duration. No adding chlorpheniramine in premedication.;Experimental Drug,Active Comparator Drug;CPM + prolongation oxaliplatin infusion ARM,Controlled ARM
Primary outcome(s): incidence of hypersensitivity reaction during oxaliplatin infusion number of event, grade
Study Design: Randomized
| 2570214 | ecrin-mdr-crc
Project description:Interventions: <Fluoropyrimidine+irinotecan+bevacizumab treatment arm>
Prior to enrollment, investigator or subinvestigator select one of the following scheduled regimens for each patient.
1.FOLFIRI+bevacizumab therapy
Bevacizumab 5 mg/kg is given as an intravenous infusion over the course of 30 min on Day 1. After that,
irinotecan 150mg/m^2 is given as an intravenous infusion over the course of at least 90 min on Day 1. At the same time, levofolinate 200mg/ m^2 is given as an infusion of the course of 2 hours on Day1. After that, fluorouracil 400 mg/ m^2 was given by rapid intravenous injection on Day 1, followed by a 46-h continuous intravenous infusion of 2400 mg/ m^2. Each cycle was 14 days, and treatment was repeated until the criteria for withdrawal of the study treatment were met.
2. S-1+irinotecan+bevacizumab therapy with a 3-week cycle
Bevacizumab 7.5 mg/kg is given as an intravenous infusion over the course of 30 min on Day 1.
After that, irinotecan 150 mg/m^2 is given as an intravenous infusion over the course of at least 90 min on Day 1.
S-1 is given orally in a dose of 40-60 mg twice daily (after breakfast and dinner) in accordance with body-surface area (80-120 mg/day), starting from after dinner on Day 1 to after breakfast on Day 15, followed by a 7-day rest. Each cycle was 21 days, and treatment was repeated until the criteria for withdrawal of the study treatment were met.
3. S-1+irinotecan+bevacizumab therapy with a 4-week cycle
Bevacizumab 5 mg/kg is given as an intravenous infusion over the course of 30 min on Day 1 and Day 15.
After that, irinotecan 100 mg/m^2 is given as an intravenous infusion over the course of at least 90 min on Day 1 and Day 15.
S-1 is given orally in a dose of 40-60 mg twice daily (after breakfast and dinner) in accordance with body-sur
Primary outcome(s): Overall survival
Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose
| 2613990 | ecrin-mdr-crc
Project description:Here, we describe a novel LC system enabling rapid protein/proteome analysis which requires <10 min analysis time. The setup consists of an autosampler harbouring two sets of 96 STAGE-tips which function as pre-columns, and a short RP analytical column, which can run a 5 min gradient. We show that the system allows the efficient combination with several popular off-line pre-fractionation methods, such as gel-electrophoresis, strong-cation exchange chromatography, but also in the analysis of interactomes obtained by affinity purification. A typical shotgun proteomics experiment, involving 36 SCX fractions of an AspN digested cell lysate, lead to the detection of over 3600 protein groups in only 3h cumulative gradient time when using a QExactive mass analyser. Application to typical various proteomics experiments such as samples from pull-downs allowed the detection of hundreds of proteins whereby a given protein’s interactome could be determined in less than 1h of accumulated gradient time. This new LC system diminishes proteome analysis time considerably, whole providing sufficient proteomic detail, and may thus also aid in bringing proteomics into the clinic where fast turn-over times are essential.
2014-12-12 | PXD001111 | Pride
Project description:Transcriptional profiling of roots from 12 days-old Arabidopsis thaliana seedlings transfered to Pi-deficient medium in hydroponic solution in a 10 min, 30 min, and 2 hrs time course period.
2013-12-12 | GSE53114 | GEO
Project description:This study looked for early response signals produced in UV-B irradiated leaves and induced in shielded leaves and shielded ears that modulate physiological responses in maize. Transcriptome profiling tracked changes in exposed and shielded organs. Metabolic profiling was examined for signaling molecules. The top 2 leaves were exposed to 10, 30, or 60 minutes of ~3x normal UV-B and then tissue samples were taken from all 3 tissue types. Over 250 transcripts are differentially expressed at least 2 fold in irradiated leaves by 10 min of UV-B. At 30 min this decreased to ~150 then increased to over 500 transcripts at 60 min. Different pathways are affected at the various time exposures and specific responses are modulated by the time of exposure. Shielded leaves had a smaller number of transcripts affected at each time point but over 60% were in common with the irradiated leaves results at 10 min. and ~20% overlaps were found at 30 and 60 min. Metabolite samples were analyzed after 5, 10, 15, 30, and 90 min of UV-B. We identified 14 compounds with a statistically significant change from untreated plants in at least one time point. Compared transciptomes of irradiated leaves, shielded leaves, and shielded ears from plants whose top 2 leaves were exposed to ~3x normal UV-B for 10, 30, and 60 minutes.
2011-07-30 | E-GEOD-30278 | biostudies-arrayexpress